| Year |
Title |
Altmetric |
| 2023
|
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Gynecologic Oncology.
170:11-18.
2023
|
|
| 2023
|
An Update on Human Papillomavirus Vaccination in the United States.
Obstetrics and Gynecology.
141:324-330.
2023
|
|
| 2022
|
Identity-related experiences of Asian American trainees in gynecologic oncology.
Gynecologic Oncology Reports.
44.
2022
|
|
| 2022
|
Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
Gynecologic Oncology.
167:146-151.
2022
|
|
| 2022
|
Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
Gynecologic Oncology.
166:503-507.
2022
|
|
| 2022
|
Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
Gynecologic Oncology.
166:481-486.
2022
|
|
| 2022
|
Increased disparities associated with black women and abnormal cervical cancer screening follow-up.
Gynecologic Oncology Reports.
42.
2022
|
|
| 2022
|
Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available.
Journal of Lower Genital Tract Disease.
26:195-201.
2022
|
|
| 2022
|
Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women.
Tumour Virus Research.
13.
2022
|
|
| 2022
|
Piloting use of an out-of-pocket cost tracker among gynecologic cancer patients.
Gynecologic Oncology Reports.
41.
2022
|
|
| 2022
|
Effect of misoprostol on type 3 transformation zone of the cervix among Cameroonian women.
Gynecologic Oncology Reports.
40.
2022
|
|
| 2022
|
Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
JAMA Network Open.
5:E222530.
2022
|
|
| 2022
|
Misoprostol and estradiol to enhance visualization of the transformation zone during cervical cancer screening: An integrative review
2022
|
|
| 2022
|
Feasibility, Safety, and Provider Perspectives of Bipolar Electrosurgical Cautery Device for (Opportunistic or Complete) Salpingectomy at the Time of Cesarean Delivery.
American Journal of Perinatology.
2022
|
|
| 2021
|
Corrigendum to “Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis” (Gynecologic Oncology (2021) 162(3) (532–538), (S0090825821005114), (10.1016/j.ygyno.2021.06.017)).
Gynecologic Oncology.
163:616-617.
2021
|
|
| 2021
|
Gynecologic oncology patients are ready for telemedicine in routine care: Results from a pre-COVID survey.
Gynecologic Oncology Reports.
38.
2021
|
|
| 2021
|
Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer.
Cancer Medicine.
10:8238-8250.
2021
|
|
| 2021
|
Erratum: 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors (Journal of Lower Genital Tract Disease (2020) 24 (102-131) DOI: 10.1097/LGT.0000000000000525).
Journal of Lower Genital Tract Disease.
25:330-331.
2021
|
|
| 2021
|
Measuring Financial Distress and Quality of Life Over Time in Patients With Gynecologic Cancer-Making the Case to Screen Early in the Treatment Course.
Jco Oncology Practice.
17:e1576-e1583.
2021
|
|
| 2021
|
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
2021
|
|
| 2021
|
Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
Gynecologic Oncology.
163:85-92.
2021
|
|
| 2021
|
A batch-effect adjusted Simon's two-stage design for cancer vaccine clinical studies.
Biometrics.
77:1075-1088.
2021
|
|
| 2021
|
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
Gynecologic Oncology.
162:532-538.
2021
|
|
| 2021
|
Evaluating Meaningful Levels of Financial Toxicity in Gynecologic Cancers.
Obstetrical and Gynecological Survey.
76:474-476.
2021
|
|
| 2021
|
Pathology findings among women with alterations in uterine bleeding patterns in cameroon.
Gynecologic Oncology Reports.
37.
2021
|
|
| 2021
|
Uterine neoplasms, version 3.2021 featured updates to the NCCN guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
19:889-895.
2021
|
|
| 2021
|
It's time to re-evaluate cervical Cancer screening after age 65.
Gynecologic Oncology.
162:200-202.
2021
|
|
| 2021
|
A population study of screening history and diagnostic outcomes of women with invasive cervical cancer.
Cancer Medicine.
10:4127-4137.
2021
|
|
| 2021
|
Evaluating meaningful levels of financial toxicity in gynecologic cancers.
International Journal of Gynecological Cancer.
31:801-806.
2021
|
|
| 2021
|
The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?.
Gynecologic Oncology.
160:800-804.
2021
|
|
| 2021
|
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Gynecologic Oncology.
160:793-799.
2021
|
|
| 2021
|
Fluorescence Imaging of the Ureter in Minimally Invasive Pelvic Surgery.
Journal of Minimally Invasive Gynecology.
28:332-341.e14.
2021
|
|
| 2021
|
When to operate, hesitate and reintegrate: society of gynecologic oncology surgical considerations during the covid-19 pandemic.
Obstetrical and Gynecological Survey.
76:88-90.
2021
|
|
| 2020
|
51st Annual Meeting of the Society of Gynecologic Oncology.
Gynecologic Oncology.
159:1.
2020
|
|
| 2020
|
Occupational Exposure to Human Papillomavirus and Vaccination for Health Care Workers.
Obstetrics and Gynecology.
136:663-665.
2020
|
|
| 2020
|
Response to Letter to the Editor Regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
Journal of Lower Genital Tract Disease.
24:426.
2020
|
|
| 2020
|
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
Gynecologic Oncology.
158:562-569.
2020
|
|
| 2020
|
Risk of second primary cancers among survivors of gynecological cancers.
Gynecologic Oncology.
158:719-726.
2020
|
|
| 2020
|
Human papillomavirus: The other invisible enemy.
Gynecologic Oncology.
158:254-255.
2020
|
|
| 2020
|
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.
Gynecologic Oncology.
158:236-243.
2020
|
|
| 2020
|
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
Gynecologic Oncology.
158:16-24.
2020
|
|
| 2020
|
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II.
Gynecologic Oncology.
158:201-207.
2020
|
|
| 2020
|
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I.
Gynecologic Oncology.
158:194-200.
2020
|
|
| 2020
|
Patterns and disparities in human papillomavirus (HPV) vaccine uptake for young female adolescents among U.S. States: NIS-teen (2008–2016).
Cancer Epidemiology, Biomarkers and Prevention.
29:1458-1467.
2020
|
|
| 2020
|
Cervical cancer, Version 1.2020 featured updates to the NCCN guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
18:660-666.
2020
|
|
| 2020
|
Cervical and oral human papillomavirus infection in women living with human immunodeficiency virus (HIV) and matched HIV-negative controls in Brazil.
Infectious Agents and Cancer.
15.
2020
|
|
| 2020
|
Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology—Retrospective insights from ATHENA.
International Journal of Cancer.
146:2599-2607.
2020
|
|
| 2020
|
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: An NRG Oncology Group study.
International Journal of Gynecological Cancer.
30:596-601.
2020
|
|
| 2020
|
2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
Journal of Lower Genital Tract Disease.
24:102-131.
2020
|
|
| 2020
|
Challenges Associated with Cervical Cancer Screening and Management in Obese Women: A Provider Perspective.
Journal of Lower Genital Tract Disease.
24:184-191.
2020
|
|
| 2020
|
Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.
Obstetrics and Gynecology.
135:869-878.
2020
|
|
| 2020
|
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Gynecologic Oncology.
157:161-166.
2020
|
|
| 2020
|
Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.
Gynecologic Oncology.
156:271-277.
2020
|
|
| 2020
|
Human papillomavirus vaccination: Ongoing challenges and future directions.
Gynecologic Oncology.
156:498-502.
2020
|
|
| 2020
|
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Gynecologic Oncology Reports.
31.
2020
|
|
| 2020
|
Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers
2020
|
|
| 2020
|
The Reliability of Intraoperative Assessment on Predicting Tumor Size, Myometrial Invasion, and Cervical Involvement in Patients with a Preoperative Diagnosis of Complex Atypical Hyperplasia or (Clinical Stage I) Endometrial Cancer: A Prospective Cohort Study
2020
|
|
| 2020
|
Cervical cancer outcome by type of health care facilities: National Cancer Database, 2004-2015.
2020
|
|
| 2020
|
The association between social media use for health related information and compliance with breast and cervical cancer screenings.
2020
|
|
| 2019
|
Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread.
Clinical Case Reports.
7:2341-2345.
2019
|
|
| 2019
|
Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report.
Gynecologic Oncology Reports.
30.
2019
|
|
| 2019
|
The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up.
Obstetrical and Gynecological Survey.
74:529-530.
2019
|
|
| 2019
|
Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012)).
Gynecologic Oncology.
154:449.
2019
|
|
| 2019
|
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
Gynecologic Oncology.
154:110-117.
2019
|
|
| 2019
|
The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
Gynecologic Oncology.
153:521-529.
2019
|
|
| 2019
|
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019
|
|
| 2019
|
Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.
Gynecologic Oncology.
153:242-247.
2019
|
|
| 2019
|
Observed Colposcopy Practice in US Community-Based Clinics: The Retrospective Control Arm of the IMPROVE-COLPO Study.
Journal of Lower Genital Tract Disease.
23:110-115.
2019
|
|
| 2019
|
Cervical cancer, version 3.2019.
Journal of the National Comprehensive Cancer Network : JNCCN.
17:64-84.
2019
|
|
| 2019
|
Gestational trophoblastic neoplasia, version 2.2019.
Journal of the National Comprehensive Cancer Network : JNCCN.
17:1374-1391.
2019
|
|
| 2019
|
The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
Gynecologic Oncology.
152:127-132.
2019
|
|
| 2018
|
Catch-up human papillomavirus vaccination: don't throw the baby out with the bathwater.
Lancet Child and Adolescent Health.
2:690-691.
2018
|
|
| 2018
|
Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women with Latent Human Papillomavirus Infections.
Obstetrics and Gynecology.
132:778-779.
2018
|
|
| 2018
|
A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer
2018
|
|
| 2018
|
Access to gynecologic oncology care and the network adequacy standard.
Cancer.
124:2677-2679.
2018
|
|
| 2018
|
Financial toxicity – An overlooked side effect.
Gynecologic Oncology.
150:3-6.
2018
|
|
| 2018
|
High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical Cytology.
Journal of Lower Genital Tract Disease.
22:207-211.
2018
|
|
| 2018
|
In Defense of a Simplified, Practical Colposcopic Terminology.
Journal of Lower Genital Tract Disease.
22:233-234.
2018
|
|
| 2018
|
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic Oncology.
149:525-530.
2018
|
|
| 2018
|
Where are the opportunities for reducing health care spending within alternative payment models?.
Jco Oncology Practice.
14:e375-e383.
2018
|
|
| 2018
|
Lessons learned from domestic and international human papillomavirus vaccination programs: a review.
American Journal of Obstetrics and Gynecology.
218:467-473.
2018
|
|
| 2018
|
Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma.
Molecular Cancer Research.
16:813-824.
2018
|
|
| 2018
|
Lessons Learned from Domestic and International Human Papillomavirus Vaccination Programs: A Review.
Obstetrical and Gynecological Survey.
73:94-95.
2018
|
|
| 2018
|
Uterine Neoplasms, Version 1.2018: Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
16:170-199.
2018
|
|
| 2018
|
Feasibility of complete salpingectomy compared with standard postpartum tubal ligation at cesarean delivery a randomized controlled trial.
Obstetrics and Gynecology.
132:20-27.
2018
|
|
| 2018
|
HPV vaccination.
Gynecologic Oncology.
148:3-4.
2018
|
|
| 2018
|
Human Papillomavirus Genotypes from Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.
Obstetrics and Gynecology.
132:261-270.
2018
|
|
| 2017
|
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
2017
|
|
| 2017
|
ASCCP Colposcopy Standards: Colposcopy Quality Improvement Recommendations for the United States.
Journal of Lower Genital Tract Disease.
21:242-248.
2017
|
|
| 2017
|
ASCCP Colposcopy Standards: How Do We Perform Colposcopy? Implications for Establishing Standards.
Journal of Lower Genital Tract Disease.
21:235-241.
2017
|
|
| 2017
|
ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice.
Journal of Lower Genital Tract Disease.
21:230-234.
2017
|
|
| 2017
|
ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic Practice.
Journal of Lower Genital Tract Disease.
21:223-229.
2017
|
|
| 2017
|
Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States.
Journal of Lower Genital Tract Disease.
21:216-222.
2017
|
|
| 2017
|
The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.
Gynecologic Oncology.
146:642-646.
2017
|
|
| 2017
|
CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ACRIN and GOG study.
Clinical Cancer Research.
23:3684-3691.
2017
|
|
| 2017
|
Optimizing secondary prevention of cervical cancer: Recent advances and future challenges.
International Journal of Gynecology and Obstetrics.
138:15-19.
2017
|
|
| 2017
|
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials.
Tumour Virus Research.
3:105-115.
2017
|
|
| 2017
|
Protection against cervical cancer versus decreasing harms from screening — What would U.S. patients and clinicians prefer, and do their preferences matter?.
Preventive Medicine.
98:31-32.
2017
|
|
| 2017
|
Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines.
Journal of Lower Genital Tract Disease.
21:87-90.
2017
|
|
| 2017
|
Transitioning from HPV 101 to HPV 202.
American Journal of Obstetrics and Gynecology.
216:206-207.
2017
|
|
| 2017
|
Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States.
PLoS One.
12.
2017
|
|
| 2017
|
Vulvar cancer, version 1.2017: Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
15:92-120.
2017
|
|
| 2017
|
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?.
Gynecologic Oncology Research and Practice.
4:7.
2017
|
|
| 2016
|
Cervical cancer screening: How do we make sense of it all and what is the right balance?.
Cancer.
122:3596-3597.
2016
|
|
| 2016
|
Expression of p16INK4A in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines.
Cancer.
122:3615-3623.
2016
|
|
| 2016
|
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.
Tumour Virus Research.
2:61-69.
2016
|
|
| 2016
|
Drawing the Line in Risk-Reducing Gynecologic Surgery in Women with a BRCA Mutation.
JAMA Oncology.
2:1409-1411.
2016
|
|
| 2016
|
Trends in Colposcopy Volume: Where Do We Go from Here?.
Journal of Lower Genital Tract Disease.
20:292-295.
2016
|
|
| 2016
|
Open vs. Minimally Invasive Hysterectomy: Commercially Insured Costs and Readmissions.
Managed care (Langhorne, Pa.).
25:40-47.
2016
|
|
| 2016
|
Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials.
Pediatrics.
138.
2016
|
|
| 2016
|
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Gynecologic Oncology.
142:25-29.
2016
|
|
| 2016
|
See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?.
Journal of Lower Genital Tract Disease.
20:243-246.
2016
|
|
| 2016
|
Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
Vaccine.
34:3171-3177.
2016
|
|
| 2016
|
HPV vaccines: Translating immunogenicity into efficacy.
Human Vaccines and Immunotherapeutics.
12:1403-1405.
2016
|
|
| 2016
|
Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Obstetrical and Gynecological Survey.
71:344-345.
2016
|
|
| 2016
|
A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.
Gynecologic Oncology.
141:364-370.
2016
|
|
| 2016
|
A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.
Journal of Lower Genital Tract Disease.
20:119-125.
2016
|
|
| 2016
|
Cervical cancer screening: Evidence behind the guidelines.
American Journal of Obstetrics and Gynecology.
214:438-443.
2016
|
|
| 2016
|
Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer.
New England Journal of Medicine.
374:738-748.
2016
|
|
| 2016
|
Reply.
American Journal of Obstetrics and Gynecology.
214:296-297.
2016
|
|
| 2016
|
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3).
Gynecologic Oncology.
140:245-252.
2016
|
|
| 2016
|
Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study.
Journal of Lower Genital Tract Disease.
20:47-51.
2016
|
|
| 2016
|
Open vs. minimally invasive hysterectomy: Commercially insured costs and readmissions.
Managed care (Langhorne, Pa.).
2016.
2016
|
|
| 2016
|
The role of human papillomavirus testing after treatment for high-grade cervical dysplasia.
Journal of Gynecologic Oncology.
27.
2016
|
|
| 2015
|
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Gynecologic Oncology.
139:413-418.
2015
|
|
| 2015
|
Uterine sarcoma, version 1.2016: Featured updates to the NCCN Guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
13:1321-1331.
2015
|
|
| 2015
|
A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in women.
Obstetrical and Gynecological Survey.
70:446-448.
2015
|
|
| 2015
|
Obesity and perioperative pulmonary complications in robotic gynecologic surgery.
American Journal of Obstetrics and Gynecology.
213:33.e1-33.e7.
2015
|
|
| 2015
|
Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance.
Journal of Lower Genital Tract Disease.
19:91-96.
2015
|
|
| 2015
|
Cervical Cancer, Version 2.2015..
Journal of the National Comprehensive Cancer Network : JNCCN.
13:395-404.
2015
|
|
| 2015
|
Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
13:395-404.
2015
|
|
| 2015
|
In reply.
Obstetrics and Gynecology.
125:492.
2015
|
|
| 2015
|
Increased cervical cancer risk associated with screening at longer intervals.
Obstetrics and Gynecology.
125:311-315.
2015
|
|
| 2015
|
Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance.
Obstetrics and Gynecology.
125:330-337.
2015
|
|
| 2015
|
Immunoprevention of human papillomavirus-associated malignancies.
Cancer Prevention Research.
8:95-104.
2015
|
|
| 2015
|
Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance.
Gynecologic Oncology.
136:178-182.
2015
|
|
| 2015
|
Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening.
Applied Health Economics and Health Policy.
13:95-107.
2015
|
|
| 2015
|
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.
PLoS One.
10.
2015
|
|
| 2015
|
Laparoscopic fluorescent visualization of the ureter with intravenous IRDye800CW.
Journal of Minimally Invasive Gynecology.
22:799-806.
2015
|
|
| 2015
|
Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial.
Gynecologic Oncology.
137:47-54.
2015
|
|
| 2014
|
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
Clinical Cancer Research.
20:5456-5467.
2014
|
|
| 2014
|
Relevance of random biopsy at the transformation zone when colposcopy is negative.
Obstetrics and Gynecology.
124:670-678.
2014
|
|
| 2014
|
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
Cancer Epidemiology, Biomarkers and Prevention.
23:1997-2008.
2014
|
|
| 2014
|
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV pseudovirions.
PLoS One.
9.
2014
|
|
| 2014
|
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
New England Journal of Medicine.
372:711-723.
2014
|
|
| 2014
|
Uterine neoplasms, version 1.2014.
Journal of the National Comprehensive Cancer Network : JNCCN.
12:248-280.
2014
|
|
| 2014
|
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study.
Gynecologic Oncology.
133:433-438.
2014
|
|
| 2014
|
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Gynecologic Oncology.
132:531-536.
2014
|
|
| 2014
|
Black race independently predicts worse survival in uterine carcinosarcoma.
Gynecologic Oncology.
133:238-241.
2014
|
|
| 2014
|
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.
Obstetrics and Gynecology.
124:881-885.
2014
|
|
| 2014
|
Outcomes of gynecologic oncology patients undergoing robotic-assisted laparoscopic procedures in a university setting.
Journal of Robotic Surgery.
8:207-211.
2014
|
|
| 2014
|
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.
Gynecologic Oncology.
133:234-237.
2014
|
|
| 2014
|
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: Analysis of women in the control arm of the randomized, controlled PATRICIA trial.
BMC Infectious Diseases.
14.
2014
|
|
| 2014
|
Tertiary prevention of cervical cancer.
Clinical Obstetrics and Gynecology.
57:316-324.
2014
|
|
| 2014
|
Update on vaccination clinical trials for HPV-related disease
2014
|
|
| 2013
|
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation.
Journal of Infectious Diseases.
208:1391-1396.
2013
|
|
| 2013
|
Erratum: HPV vaccination in women treated for CIN2/3: It's still all about prevention (Gynecologic Oncology (2013) 130 (255-256)).
Gynecologic Oncology.
131:499.
2013
|
|
| 2013
|
Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.
Gynecologic Oncology.
130:421-425.
2013
|
|
| 2013
|
HPV vaccination in women treated for CIN2/3: It's still all about prevention.
Gynecologic Oncology.
130:255-256.
2013
|
|
| 2013
|
In reply..
Obstetrics and Gynecology.
122:393.
2013
|
|
| 2013
|
Recommendations for a national agenda to substantially reduce cervical cancer.
Cancer Causes and Control.
24:1583-1593.
2013
|
|
| 2013
|
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins.
Gynecologic Oncology.
129:528-532.
2013
|
|
| 2013
|
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
Journal of Virology.
87:6127-6136.
2013
|
|
| 2013
|
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Journal of Lower Genital Tract Disease.
17.
2013
|
|
| 2013
|
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Obstetrics and Gynecology.
121:829-846.
2013
|
|
| 2013
|
Cervical cancer: Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
11:320-343.
2013
|
|
| 2013
|
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women.
Journal of Adolescent Health.
52:322-329.
2013
|
|
| 2013
|
Optimization of Multimeric Human Papillomavirus L2 Vaccines.
PLoS One.
8.
2013
|
|
| 2013
|
Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women
2013
|
|
| 2013
|
High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the cervista HPV HR test.
Journal of Lower Genital Tract Disease.
17:51-57.
2013
|
|
| 2013
|
Human papillomavirus: What every provider should know.
American Journal of Obstetrics and Gynecology.
208:169-175.
2013
|
|
| 2013
|
Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors.
Gynecologic Oncology.
131:59-62.
2013
|
|
| 2012
|
New insights into cervical cancer screening.
Journal of Gynecologic Oncology.
23:282-287.
2012
|
|
| 2012
|
Survey of Robotic Surgery Credentialing Requirements for Physicians Completing OB/GYN Residency.
Journal of Minimally Invasive Gynecology.
19:589-592.
2012
|
|
| 2012
|
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data.
British medical journal.
344.
2012
|
|
| 2012
|
TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
Cancer Epidemiology, Biomarkers and Prevention.
21:273-279.
2012
|
|
| 2012
|
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
2012
|
|
| 2011
|
A multimeric L2 vaccine for prevention of animal papillomavirus infections.
Virology.
420:43-50.
2011
|
|
| 2011
|
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus.
PLoS One.
6.
2011
|
|
| 2011
|
Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.
Gynecologic Oncology.
123:54-57.
2011
|
|
| 2011
|
A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma.
Gynecologic Oncology.
122:604-607.
2011
|
|
| 2011
|
Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment.
Obstetrics and Gynecology.
118:548-553.
2011
|
|
| 2011
|
Adaptive data-driven inventory control with censored demand based on Kaplan-Meier estimator.
Operations Research.
59:929-941.
2011
|
|
| 2011
|
Factors Associated with Intention to Vaccinate a Daughter against HPV: A Statewide Survey in Alabama.
Journal of Pediatric and Adolescent Gynecology.
24:166-171.
2011
|
|
| 2011
|
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma.
International Journal of Gynecological Cancer.
21:494-499.
2011
|
|
| 2011
|
Invasive cervical cancer and screening: What are the rates of unscreened and underscreened women in the modern era?.
Journal of Lower Genital Tract Disease.
15:110-113.
2011
|
|
| 2011
|
Referral patterns and incidence of cervical intraepithelial neoplasia in adolescent and pregnant patients: The impact of the 2006 guidelines.
Journal of Lower Genital Tract Disease.
15:124-127.
2011
|
|
| 2010
|
Cervical cancer: Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
8:1388-1416.
2010
|
|
| 2010
|
The changing face of cervical cancer screening in the United States.
Journal of the National Comprehensive Cancer Network : JNCCN.
8:1329-1330.
2010
|
|
| 2010
|
Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
Gynecologic Oncology.
119:237-242.
2010
|
|
| 2010
|
What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?.
Gynecologic Oncology.
117:481-485.
2010
|
|
| 2010
|
Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Gynecologic Oncology.
117:248-254.
2010
|
|
| 2010
|
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
2010
|
|
| 2010
|
How does public policy impact cervical screening and vaccination strategies?.
Gynecologic Oncology.
119:175-180.
2010
|
|
| 2010
|
Robotic surgery in gynecologic oncology fellowship programs in the USA: A survey of fellows and fellowship directors.
International Journal of Medical Robotics and Computer Assisted Surgery.
6:405-412.
2010
|
|
| 2009
|
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Gynecologic Oncology.
115:244-248.
2009
|
|
| 2009
|
Introduction: Human Papillomavirus-A Clear, Present, and Common Danger.
American Journal of Medicine.
122.
2009
|
|
| 2009
|
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Gynecologic Oncology.
114:242-245.
2009
|
|
| 2009
|
Comprehensive surgical staging for endometrial cancer in obese patients.
Obstetrics and Gynecology.
114:16-21.
2009
|
|
| 2009
|
Human papillomavirus infection.
Obstetrics and Gynecology.
114:139-143.
2009
|
|
| 2009
|
The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia.
Journal of Lower Genital Tract Disease.
13:137-144.
2009
|
|
| 2009
|
The management of cervical intraepithelial neoplasia during pregnancy: Is colposcopy necessary?.
Journal of Lower Genital Tract Disease.
13:182-185.
2009
|
|
| 2009
|
Can primary recurrences in surgical stage I-II uterine papillary serous carcinoma (UPSC) patients be salvaged?.
Journal of Clinical Oncology.
27:e16503.
2009
|
|
| 2009
|
In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer..
Journal of Clinical Oncology.
27:5503.
2009
|
|
| 2009
|
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
Cancer.
115:2119-2127.
2009
|
|
| 2009
|
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
Immunology and Cell Biology.
87:287-299.
2009
|
|
| 2009
|
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts
2009
|
|
| 2009
|
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Gynecologic Oncology.
112:558-562.
2009
|
|
| 2009
|
Early-stage endometrial cancer: Is adjuvant radiation really warranted?.
Clinical Ovarian and other Gynecologic Cancer.
2:90-93.
2009
|
|
| 2009
|
Uterine neoplasms.
Journal of the National Comprehensive Cancer Network : JNCCN.
7:498-531.
2009
|
|
| 2008
|
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Gynecologic Oncology.
111:89-94.
2008
|
|
| 2008
|
Erratum: Evaluation of the interim analysis from the PATRICIA study group: Efficacy of a vaccine against HPV 16 and 18 (Expert Review of Anticancer Therapy (2008) vol. 8 (5) (701-705))
2008
|
|
| 2008
|
Evaluation of the interim analysis from the PATRICIA study group: Efficacy of a vaccine against HPV 16 and 18
2008
|
|
| 2008
|
Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects
2008
|
|
| 2008
|
Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.
Vaccine.
26:4314-4319.
2008
|
|
| 2008
|
Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001).
Gynecologic Oncology.
110:270.
2008
|
|
| 2008
|
Pretreatment with cisplatin enhances E7-Specific CD8+ T-cell -mediated antitumor immunity induced by DNA vaccination.
Clinical Cancer Research.
14:3185-3192.
2008
|
|
| 2008
|
Age considerations when vaccinating against HPV.
Gynecologic Oncology.
109.
2008
|
|
| 2008
|
Initial lessons learned in HPV vaccination.
Gynecologic Oncology.
109.
2008
|
|
| 2008
|
Lynch syndrome in women less than 50 years of age with endometrial cancer.
Obstetrics and Gynecology.
111:1161-1166.
2008
|
|
| 2008
|
The future of vaccines for cervical cancer.
Gynecologic Oncology.
109.
2008
|
|
| 2008
|
Lipoxygenase pathway receptor expression in ovarian cancer.
Reproductive Sciences.
15:321-326.
2008
|
|
| 2008
|
Cervical cancer.
Journal of the National Comprehensive Cancer Network : JNCCN.
6:14-36.
2008
|
|
| 2008
|
Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN.
Journal of the National Comprehensive Cancer Network : JNCCN.
6:96-100.
2008
|
|
| 2008
|
The current and future role of screening in the era of HPV vaccination.
Gynecologic Oncology.
109.
2008
|
|
| 2007
|
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma [15].
Obstetrics and Gynecology.
110:933-934.
2007
|
|
| 2007
|
Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experience.
International Journal of Gynecological Cancer.
17:998-1002.
2007
|
|
| 2007
|
Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experience.
International Journal of Gynecological Cancer.
17:886-889.
2007
|
|
| 2007
|
A multi-institutional review of outcomes of endometrial stromal sarcoma.
Gynecologic Oncology.
105:630-634.
2007
|
|
| 2007
|
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma.
Obstetrics and Gynecology.
109:1388-1395.
2007
|
|
| 2007
|
Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia.
British Journal of Cancer.
96:1480-1483.
2007
|
|
| 2007
|
Clinical and pathologic correlates in surgical stage II endometrial carcinoma.
Obstetrics and Gynecology.
109:1062-1067.
2007
|
|
| 2007
|
New advances in vaccine technology and improved cervical cancer prevention.
Obstetrics and Gynecology.
109:1187-1192.
2007
|
|
| 2007
|
Diagnostic loop electrosurgical excisional procedure for discrepancy: Do preoperative factors predict presence of significant cervical intraepithelial neoplasia?.
Journal of Lower Genital Tract Disease.
11:69-72.
2007
|
|
| 2007
|
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Gynecologic Oncology.
104:591-595.
2007
|
|
| 2007
|
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer [13].
Obstetrics and Gynecology.
109:785.
2007
|
|
| 2007
|
LUMA™ cervical imaging system.
Expert Review of Medical Devices.
4:121-129.
2007
|
|
| 2007
|
Primary appendiceal cancer: Gynecologic manifestations and treatment options.
Gynecologic Oncology.
104:602-606.
2007
|
|
| 2007
|
Autoclave sterilization of instruments used on women with cervical neoplasia is an effective method of eradicating residual human papillomavirus DNA: A polymerase chain reaction-based evaluation.
Journal of Lower Genital Tract Disease.
11:12-17.
2007
|
|
| 2007
|
Gene expression profiling of women with varying degrees of cervical intraepithelial neoplasia.
Journal of Lower Genital Tract Disease.
11:25-28.
2007
|
|
| 2007
|
Treatment considerations in advanced endometrial cancer.
Current Oncology Reports.
9:494-498.
2007
|
|
| 2006
|
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer.
Obstetrics and Gynecology.
108:1375-1379.
2006
|
|
| 2006
|
Cervical intraepithelial neoplasia in adolescent women: Incidence and treatment outcomes.
Obstetrics and Gynecology.
108:1369-1374.
2006
|
|
| 2006
|
Therapeutic role of lymph node resection in endometrioid corpus cancer: A study of 12,333 patients.
Cancer.
107:1823-1830.
2006
|
|
| 2006
|
Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based Chemotherapy.
Journal of the American College of Surgeons.
203:527-532.
2006
|
|
| 2006
|
Novel methods to treat and prevent human papillomavirus infection.
Expert Review of Anti-infective Therapy.
4:593-600.
2006
|
|
| 2006
|
Hormonal contraception and false-positive cervical cytology: Is there an association?.
Journal of Lower Genital Tract Disease.
10:102-106.
2006
|
|
| 2006
|
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients
2006
|
|
| 2006
|
Carcinosarcoma of the ovary - A case series.
Gynecologic Oncology.
100:128-132.
2006
|
|
| 2006
|
Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters).
Gynecologic Oncology.
100:219-220.
2006
|
|
| 2005
|
Optical detection of cervical neoplasia: results from an internally-controlled multicenter study..
Gynecologic Oncology.
99:S53.
2005
|
|
| 2005
|
The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Gynecologic Oncology.
99:557-563.
2005
|
|
| 2005
|
A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses.
Gynecologic Oncology.
99:443-446.
2005
|
|
| 2005
|
Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report.
Gynecologic Oncology.
98:155-157.
2005
|
|
| 2005
|
Feasibility of hand-assisted laparoscopic surgery (HALS) in gynecologic oncology patients..
Journal of Clinical Oncology.
23:5153.
2005
|
|
| 2005
|
Utility of immunohistochemistry tissue array in the prediction of epithelial ovarian carcinoma response to therapy..
Journal of Clinical Oncology.
23:5033.
2005
|
|
| 2005
|
A case report of rhabdomyosarcoma of the uterus associated with uterine inversion.
Gynecologic Oncology.
96:850-853.
2005
|
|
| 2005
|
A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy?.
Journal of Lower Genital Tract Disease.
9:2-6.
2005
|
|
| 2005
|
Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis.
Gynecologic Oncology.
97:387-394.
2005
|
|
| 2005
|
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy.
Gynecologic Oncology.
98:309-312.
2005
|
|
| 2005
|
What is the correct management of stage i upsc?: 0013.
International Journal of Gynecological Cancer.
15:405-406.
2005
|
|
| 2004
|
Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.
Journal of Gene Medicine.
6:1281-1289.
2004
|
|
| 2004
|
Protrusio acetabuli presenting as a complex pelvic mass after total hip arthroplasty.
Obstetrics and Gynecology.
104:1187-1189.
2004
|
|
| 2004
|
High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus.
Journal of Lower Genital Tract Disease.
8:298-303.
2004
|
|
| 2004
|
A double-blinded, randomized controlled trial of oxytocin at the beginning versus the end of the third stage of labor for prevention of postpartum hemorrhage.
Gynecologic and Obstetric Investigation.
58:72-76.
2004
|
|
| 2004
|
Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients..
Journal of Clinical Oncology.
22:5044.
2004
|
|
| 2004
|
Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy..
Journal of Clinical Oncology.
22:5083.
2004
|
|
| 2004
|
Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series
2004
|
|
| 2004
|
HPV triage of patients with ASCUS cervical Pap smears.
Sexuality, reproduction & menopause.
2:146-153.
2004
|
|
| 2004
|
Optical detection of high-grade cervical intraepithelial neoplasia in vivo: Results of a 604-patient study.
American Journal of Obstetrics and Gynecology.
190:1249-1257.
2004
|
|
| 2004
|
Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.
Gynecologic Oncology.
93:429-434.
2004
|
|
| 2003
|
Human Papillomavirus Triage of Patients with Atypical Squamous Cells of Undetermined Significance on Cervical Papanicolaou Smear.
Annals of the Academy of Medicine, Singapore.
32:590-596.
2003
|
|
| 2003
|
Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy.
Gynecologic Oncology.
89:295-300.
2003
|
|
| 2003
|
Primary extrarenal rhabdoid tumor of the ovary: A case report
2003
|
|
| 2003
|
Complications of indwelling venous access devices in patients with gynecologic malignancies.
Gynecologic Oncology.
91:591-595.
2003
|
|
| 2003
|
Postmenopausal uterine inversion associated with endometrial polyps.
Obstetrics and Gynecology.
102:521-523.
2003
|
|
| 2003
|
Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
Gynecologic Oncology.
91:470-475.
2003
|
|
| 2002
|
Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture.
Obstetrics and Gynecology.
100:1061-1063.
2002
|
|
| 2002
|
Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture..
Obstetrics and Gynecology.
100:1061-1063.
2002
|
|
| 2002
|
Uterine leiomyosarcoma metastatic to the thyroid.
Obstetrics and Gynecology.
100:1122-1124.
2002
|
|
| 2002
|
Uterine leiomyosarcoma metastatic to the thyroid..
Obstetrics and Gynecology.
100:1122-1124.
2002
|
|
| 2002
|
Immunotherapy of ovarian cancer.
Expert Opinion on Biological Therapy.
2:409-417.
2002
|
|
| 2002
|
A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical Cancer Research.
8:2806-2811.
2002
|
|
| 2002
|
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis.
Gynecologic Oncology.
87:57-63.
2002
|
|
| 2002
|
Conservative management of Stage I endometrial carcinoma after surgical staging.
Gynecologic Oncology.
84:194-200.
2002
|
|
| 2002
|
Gene therapy..
Cancer Treatment and Research.
107:133-157.
2002
|
|
| 2001
|
Gene therapy and cervical cancer: An overview.
Cme Journal of Gynecologic Oncology.
6:377-382.
2001
|
|
| 2001
|
Endometrial carcinoma.
Current Treatment Options in Oncology.
2:129-135.
2001
|
|
| 2001
|
Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix.
Gynecologic Oncology.
83:370-377.
2001
|
|
